Notably there were no hyperglycemia‐related treatment disruptions at all in patients taking selective PI3K inhibitor for a non‐α isoform, whereas in the rest of the cohort 12% experienced hyperglycemia‐related treatment disruptions, including 11% with dose interruptions, 9% with dose reductions, and 2% with hospitalization for hyperglycemia management. The gene discussed is PIK3CA; the disease is Hyperglycemia.